Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair

Conclusions:
FATSI screening showed that a substantial number of patients’ tumors have FA functional deficiency, which led to germline alterations in several patients’ tumors. Veliparib alone or with MMC was safely administered to these patients and produced clinical benefit in some. However, a better understanding of resistance mechanisms in this setting is needed.

Source: JNCI - February 4, 2016 Category: Cancer & Oncology Authors: Villalona-Calero, M. A., Duan, W., Zhao, W., Shilo, K., Schaaf, L. J., Thurmond, J., Westman, J. A., Marshall, J., Xiaobai, L., Ji, J., Rose, J., Lustberg, M., Bekaii-Saab, T., Chen, A., Timmers, C. Tags: Article Source Type: research